预约演示
更新于：2026-02-27
Clemastine Fumarate
富马酸氯马斯汀
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 (+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine、(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine、Clemastine + [9] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H30ClNO5 |
InChIKeyPMGQWSIVQFOFOQ-YKVZVUFRSA-N |
CAS号14976-57-9 |
关联
24
项与 富马酸氯马斯汀 相关的临床试验NCT07304024
A Double-Blinded, Placebo-Controlled, Randomized, Phase 1/2a Clinical Study to Test the Safety and Efficacy of a Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
ChiCTR2500109656
Clemastine Fumarate Improves Cognitive Function and Prognosis in Patients with Ruptured Intracranial Aneurysms
NCT06591091
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
100 项与 富马酸氯马斯汀 相关的临床结果
登录后查看更多信息
100 项与 富马酸氯马斯汀 相关的转化医学
登录后查看更多信息
100 项与 富马酸氯马斯汀 相关的专利（医药）
登录后查看更多信息
821
项与 富马酸氯马斯汀 相关的文献（医药）2026-05-01NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Myelin damage in major depressive disorder: Insights from neuroimaging, molecular mechanisms, and therapeutic perspectives
Review
作者: Wang, Yile ; Xiong, Zhen ; Chen, Man ; Zhu, Zhou
Depression has been increasingly recognized as a disorder involving structural and functional abnormalities of the white matter, with myelin pathology emerging as a consistent feature observed across multiple studies. This review aimed to synthesize evidence from neuroimaging, postmortem, transcriptomic, and experimental studies to elucidate the relationship between myelin damage and depressive pathophysiology. Major depressive disorder is consistently associated with reduced white matter integrity in emotion-related brain regions, including the medial prefrontal cortex, hippocampus, amygdala, and corpus callosum. Histopathological analyses reveal decreased oligodendrocyte density, impaired differentiation of oligodendrocyte progenitor cells, and downregulation of critical myelin-associated genes, alongside microglial activation and astrocytic dysfunction that exacerbate demyelination. Animal models demonstrate that demyelination correlates with depression-like behaviors and that depression interventions-such as clemastine, venlafaxine, or enriched environments-can partially restore myelin structure and alleviate behavioral deficits. These findings suggest that myelin impairment is not solely a downstream consequence of depression but may play an active role in its onset and progression. Targeting myelin protection and repair represents a promising therapeutic avenue. Future clinical studies are urgently needed to determine causal mechanisms and evaluate the efficacy of remyelination-based strategies in patients with depression.
2026-03-01CLINICAL OTOLARYNGOLOGY
Does Oral Antihistamine Use Reduce the Risk of Salivary Fistula Following Superficial Parotidectomy? A Retrospective Study
Article
作者: Afifoğlu, Malik ; Eravcı, Fakih Cihat ; Korkmaz, Mehmet ; Abakır, Nursultan ; Arbağ, Hamdi ; Eryılmaz, Mehmet Akif
ABSTRACT:
Objective:
This study aimed to evaluate the effect of postoperative oral antihistamine (clemastine) use on the incidence of salivary fistula and sialocele in patients undergoing superficial parotidectomy.
Materials and Methods:
A retrospective analysis was conducted on 202 patients who underwent superficial parotidectomy for benign parotid tumours at the Department of Otolaryngology—Head and Neck Surgery, Necmettin Erbakan University, between 2020 and 2024. All patients were prescribed clemastine‐containing antihistamines postoperatively; however, they were divided into two groups based on their access to and use of the medication. The development of salivary fistula and sialocele was assessed clinically. Data were analysed using Fisher's exact test, and
p
< 0.05 was considered statistically significant.
Results:
Salivary fistula was observed in 5 of 164 patients (3.0%) in the antihistamine group and in 5 of 38 patients (13.2%) in the non‐user group. This difference was statistically significant (
p
= 0.022). The incidence of sialocele was three (1.8%) in the antihistamine group and two (5.3%) in the non‐user group, with no significant difference between the groups (
p
= 0.237). The most common side effects in patients receiving antihistamines were drowsiness (12.1%), accommodation disorders (9.1%) and other mild anticholinergic symptoms.
Conclusion:
Oral antihistamine use following superficial parotidectomy may significantly reduce the incidence of salivary fistula. Most adverse effects were mild and tolerable. These findings suggest a potential benefit of antihistamines in the prevention of postoperative complications.
2026-02-24PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination
Article
作者: Baron-Van Evercooren, Anne ; Sarrazin, Nadège ; Arcizet, Fabrice ; Pouget, Pierre ; Bennett, Daniel J. ; Langui, Dominique ; Moissonnier, Pierre ; Cordano, Christian ; Arab, Rafik ; Abdelhak, Ahmed ; Bachelin, Corinne ; Chazot, Jérémy ; Green, Ari J. ; Nouvel-Jaillard, Céline ; Halait, Harkeerat ; Brazhnikova, Elena
Promotion of remyelination has become a new therapeutic avenue, to prevent neuronal degeneration and promote recovery in white matter diseases such as multiple sclerosis. Clemastine fumarate among several promyelinating agents, has been validated as a promyelinating agent in rodents and has led to a first successful double-blind, placebo-controlled clinical trial evaluating a remyelinating therapy for multiple sclerosis (MS) [A. J. Green
et al.
,
Lancet390
, 2481–2489 (2017)]. To date, most of promyelinating strategies have been developed in short-lived rodent models of demyelination, which spontaneously repair. Well-defined nonhuman primate models closer to man would allow to efficiently advance therapeutic approaches, and namely to assess noninvasively, their efficacy in promoting functional repair. We developed a nonhuman primate model of optic nerve demyelination which leads to failed remyelination, progressive neuronal degeneration, and visual dysfunction, thus recapitulating several features of MS lesions and providing the missing link to translate emerging preclinical therapies to the clinic for myelin disorders such as multiple sclerosis [N. Sarrazin
et al.
,
Proc. Natl. Acad. Sci. U.S.A.119
, e2115973119 (2022)]. We used this model to assay the therapeutic benefits of clemastine. Our histological and ultrastructural findings show that clemastine is able to overcome the failed remyelination of the nonhuman primate optic nerve. We also used visual evoked potential, optical coherence tomography, and electroretinogram as noninvasive means to follow up the optic nerve de/remyelination process and correlated these findings with postmortem analysis to establish the safety and efficacy of clemastine therapy in promoting functional and morphological recovery in nonhuman primates. We demonstrate that clemastine can overcome chronic demyelination in nonhuman primates.
20
项与 富马酸氯马斯汀 相关的新闻（医药）
2026-02-08
临床3期细胞疗法临床1期临床结果
2026-01-30
100 项与 富马酸氯马斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 1977-02-25 | |
| 普通感冒 | 日本 | 1970-01-17 | |
| 皮炎 | 日本 | 1970-01-17 | |
| 湿疹 | 日本 | 1970-01-17 | |
| 瘙痒 | 日本 | 1970-01-17 | |
| 过敏性鼻炎 | 日本 | 1970-01-17 | |
| 荨麻疹 | 日本 | 1970-01-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性鼻炎 | 临床2期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Intravenous Clemastine | 餘淵艱鹹簾醖繭築窪構(製製糧築觸蓋顧觸衊範) = 醖鏇範鬱構襯選顧蓋齋 餘獵醖艱夢齋構憲衊築 (繭糧鹹廠衊夢醖繭顧積, -3.4 ~ 1.1) | 积极 | 2024-06-07 | |
餘淵艱鹹簾醖繭築窪構(製製糧築觸蓋顧觸衊範) = 夢網築襯廠膚餘選遞範 餘獵醖艱夢齋構憲衊築 (繭糧鹹廠衊夢醖繭顧積, -3.4 ~ 1.1) | |||||||
临床2期 | 50 | (Clemastine) | 襯鏇繭壓願鹽製膚願壓(壓糧齋壓鑰鑰構製糧積) = 範網鏇醖遞淵窪衊繭選 構糧築築願夢繭糧醖願 (鹽繭積範獵製憲襯憲淵, 11.5) 更多 | - | 2021-07-15 | ||
Placebo+clemastine (Placebo) | 襯鏇繭壓願鹽製膚願壓(壓糧齋壓鑰鑰構製糧積) = 簾壓獵積範鬱網鹹壓窪 構糧築築願夢繭糧醖願 (鹽繭積範獵製憲襯憲淵, 10.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用